share_log

Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $54

Benzinga ·  Oct 16, 2024 06:37  · Ratings

Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and raises the price target from $32 to $54.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment